Indeed, AURKA inhibitors, MLN8054 and MLN8237 (Alisertib), are able to disrupt this interaction, leading to N-MYC degradation and subsequently cell death and differentiation in neuroblastoma cells [45, 50]. The gene discussed is MYCN; the disease is neuroblastoma.